Cargando…
Adipokines as Clinically Relevant Therapeutic Targets in Obesity
Adipokines provide an outstanding role in the comprehensive etiology of obesity and may link adipose tissue dysfunction to further metabolic and cardiovascular complications. Although several adipokines have been identified in terms of their physiological roles, many regulatory circuits remain uncle...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216759/ https://www.ncbi.nlm.nih.gov/pubmed/37239098 http://dx.doi.org/10.3390/biomedicines11051427 |
_version_ | 1785048375109877760 |
---|---|
author | Würfel, Marleen Blüher, Matthias Stumvoll, Michael Ebert, Thomas Kovacs, Peter Tönjes, Anke Breitfeld, Jana |
author_facet | Würfel, Marleen Blüher, Matthias Stumvoll, Michael Ebert, Thomas Kovacs, Peter Tönjes, Anke Breitfeld, Jana |
author_sort | Würfel, Marleen |
collection | PubMed |
description | Adipokines provide an outstanding role in the comprehensive etiology of obesity and may link adipose tissue dysfunction to further metabolic and cardiovascular complications. Although several adipokines have been identified in terms of their physiological roles, many regulatory circuits remain unclear and translation from experimental studies to clinical applications has yet to occur. Nevertheless, due to their complex metabolic properties, adipokines offer immense potential for their use both as obesity-associated biomarkers and as relevant treatment strategies for overweight, obesity and metabolic comorbidities. To provide an overview of the current clinical use of adipokines, this review summarizes clinical studies investigating the potential of various adipokines with respect to diagnostic and therapeutic treatment strategies for obesity and linked metabolic disorders. Furthermore, an overview of adipokines, for which a potential for clinical use has been demonstrated in experimental studies to date, will be presented. In particular, promising data revealed that fibroblast growth factor (FGF)-19, FGF-21 and leptin offer great potential for future clinical application in the treatment of obesity and related comorbidities. Based on data from animal studies or other clinical applications in addition to obesity, adipokines including adiponectin, vaspin, resistin, chemerin, visfatin, bone morphogenetic protein 7 (BMP-7) and tumor necrosis factor alpha (TNF-α) provide potential for human clinical application. |
format | Online Article Text |
id | pubmed-10216759 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102167592023-05-27 Adipokines as Clinically Relevant Therapeutic Targets in Obesity Würfel, Marleen Blüher, Matthias Stumvoll, Michael Ebert, Thomas Kovacs, Peter Tönjes, Anke Breitfeld, Jana Biomedicines Review Adipokines provide an outstanding role in the comprehensive etiology of obesity and may link adipose tissue dysfunction to further metabolic and cardiovascular complications. Although several adipokines have been identified in terms of their physiological roles, many regulatory circuits remain unclear and translation from experimental studies to clinical applications has yet to occur. Nevertheless, due to their complex metabolic properties, adipokines offer immense potential for their use both as obesity-associated biomarkers and as relevant treatment strategies for overweight, obesity and metabolic comorbidities. To provide an overview of the current clinical use of adipokines, this review summarizes clinical studies investigating the potential of various adipokines with respect to diagnostic and therapeutic treatment strategies for obesity and linked metabolic disorders. Furthermore, an overview of adipokines, for which a potential for clinical use has been demonstrated in experimental studies to date, will be presented. In particular, promising data revealed that fibroblast growth factor (FGF)-19, FGF-21 and leptin offer great potential for future clinical application in the treatment of obesity and related comorbidities. Based on data from animal studies or other clinical applications in addition to obesity, adipokines including adiponectin, vaspin, resistin, chemerin, visfatin, bone morphogenetic protein 7 (BMP-7) and tumor necrosis factor alpha (TNF-α) provide potential for human clinical application. MDPI 2023-05-11 /pmc/articles/PMC10216759/ /pubmed/37239098 http://dx.doi.org/10.3390/biomedicines11051427 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Würfel, Marleen Blüher, Matthias Stumvoll, Michael Ebert, Thomas Kovacs, Peter Tönjes, Anke Breitfeld, Jana Adipokines as Clinically Relevant Therapeutic Targets in Obesity |
title | Adipokines as Clinically Relevant Therapeutic Targets in Obesity |
title_full | Adipokines as Clinically Relevant Therapeutic Targets in Obesity |
title_fullStr | Adipokines as Clinically Relevant Therapeutic Targets in Obesity |
title_full_unstemmed | Adipokines as Clinically Relevant Therapeutic Targets in Obesity |
title_short | Adipokines as Clinically Relevant Therapeutic Targets in Obesity |
title_sort | adipokines as clinically relevant therapeutic targets in obesity |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216759/ https://www.ncbi.nlm.nih.gov/pubmed/37239098 http://dx.doi.org/10.3390/biomedicines11051427 |
work_keys_str_mv | AT wurfelmarleen adipokinesasclinicallyrelevanttherapeutictargetsinobesity AT bluhermatthias adipokinesasclinicallyrelevanttherapeutictargetsinobesity AT stumvollmichael adipokinesasclinicallyrelevanttherapeutictargetsinobesity AT ebertthomas adipokinesasclinicallyrelevanttherapeutictargetsinobesity AT kovacspeter adipokinesasclinicallyrelevanttherapeutictargetsinobesity AT tonjesanke adipokinesasclinicallyrelevanttherapeutictargetsinobesity AT breitfeldjana adipokinesasclinicallyrelevanttherapeutictargetsinobesity |